Prange Group and Adragos Pharma Acquire Fresenius Kabi’s Manufacturing Site

Prange Group and its affiliate Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for the acquisition of the leading sterile  pharmaceutical production site in Halden, Norway. As part of the transaction, Fresenius Kabi will strike a long-term supply agreement for products manufactured at the Halden site.

The Halden site, situated at strategic crossroads in Norway, is one of the largest and most advanced  sterile production facilities in Northern Europe. The state-of-the-art capabilities include the production  of IV bags, ampoules, blow-fill-seal technology, and other pharmaceutical dosage forms. The site was not only a cornerstone of Fresenius Kabi's manufacturing capabilities in the Nordics, but already caters to other prominent pharma customers as a contract manufacturer. 

The Prange Group is a leading German family office with a long track record of successfully investing in and growing pharmaceutical companies and CDMOs. The Prange Group was invested in Adragos Pharma from the beginning and remains a cornerstone shareholder, reflecting a long-term commitment  to the sector. 

Otto Prange, Chairman of the Prange Group, shared his vision for the acquisition: “Our collaboration with Fresenius Kabi is a strategic step that resonates with Prange Group's commitment to quality and reliability in supplying our customers and in caring for patients globally. Through our partnership with Adragos Pharma, we are set to enhance the potential of the Halden site, which is a testament to the dedication of Halden’s workforce. Recognising the value of our employees, we are dedicated to fostering their expertise, ensuring that the legacy and integrity of the site continue to thrive.” 

Adragos Pharma has gained attention as Europe’s fastest-growing CDMO and received several awards in recent years. Central to Adragos Pharma’s growth is a strong emphasis on customer service and focus  on highest manufacturing standards from production sites in Europe and Japan.  

Dr. Andreas Raabe, Adragos Pharma’s CEO, stated “The inclusion of the Halden site into Adragos  Pharma’s network is a fantastic addition to our network. Halden has a broad range of technologies and  offers considerable expansion space that allows us to tailor our services to the specific needs of our  customers. We will be positioning the site as one of Europe's premier sterile production facilities.” 

Detailed terms of the transaction will not be disclosed. The transaction is subject to customary conditions precedents.